Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03705637 · ClinicalTrials.gov registry record · Early Phase 1
Liposomal Bupivicaine for Skin Graft Donor Sites in Burn Patients
A Early Phase 1 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT03705637: Clinical Trial Early Phase 1 study, sponsored by Massachusetts General Hospital.
NCT03705637 is a Early Phase 1 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03705637, a Early Phase 1 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Burn injuries are painful to patients and the sources of pain result from many areas including: the injury itself, wound care, and surgery. Inpatients that require surgical skin grafting is often required and the donor site of a skin graft is quite painful for patients. The investigators try to minimize that pain with local anesthetic as well as a combination of pain medications, the donor site pain lasts for days and is what patients often report as being the most painful part of their burn care. There has been the development of a new form of local anesthesia that can last up to 72 hours when injected into tissue. Based on encouraging results in the literature in areas outside of burns, this study aims to evaluate whether administration of this medication at the time of surgery can help improve pain for burn patients in the postoperative period.
Interventions
- DRUG Exparel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-06-01 |
| Est. Completion | 2020-03-24 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03705637
The ClinicalTrials.gov registry entry for NCT03705637 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Exparel is the first listed.
NCT03705637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03705637 about?
NCT03705637 is a clinical study titled "Liposomal Bupivicaine for Skin Graft Donor Sites in Burn Patients". Burn injuries are painful to patients and the sources of pain result from many areas including: the injury itself, wound care, and surgery. Inpatients that require surgical skin grafting is often required and the donor site of a skin graft is quite painful for patients. The investigators try to mini...
What is the current status of trial NCT03705637?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2019-06-01. Estimated completion is 2020-03-24.
What interventions are being tested in trial NCT03705637?
The interventions under investigation include: Exparel (DRUG).
Who is sponsoring clinical trial NCT03705637?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.